[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sichuan Cancer Hospital and Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":494},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,48,75,106,126,149,174,195,215,239,259,281,299,321,341,362,386,410,430,452,474],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100640926","preoperative-decision-making-in-patients-with-pulmonary-nodules-suspected-of-lung-cancer-100640926",false,"NCT07590596","Preoperative Decision-Making in Patients With Pulmonary Nodules Suspected of Lung Cancer","Preoperative Decision-Making Characteristics and Associated Mechanisms in Patients With Pulmonary Nodules Suspected of Lung Cancer","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Adult patients with pulmonary nodules that are highly suspected of malignancy based on clinical and radiological assessment.\n3. No definite pathological diagnosis of lung cancer before enrollment.\n4. Patients who are facing preoperative clinical decision-making with more than one reasonable management option, such as surgery, additional diagnostic evaluation, or follow-up.\n5. Able to understand the study procedures and complete the study questionnaires.\n6. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients without a real clinical decision-making choice regarding the management of the pulmonary nodule.\n2. Patients with severe cognitive impairment or a history of severe psychiatric disease that would interfere with valid questionnaire completion.\n3. Patients who are unable to communicate effectively with the study staff.\n4. Patients who decline to participate or are unable to provide written informed consent.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Patients with pulmonary nodules that are highly suspected to be lung cancer often need to make important treatment decisions before a definite pathological diagnosis is available. These decisions may include whether to undergo surgery, whether to continue follow-up, whether to have further diagnostic tests, and how to understand the potential benefits and risks of different management options.\n\nThis prospective observational study aims to describe the preoperative decision-making status of adult patients with pulmonary nodules suspected of lung cancer. The study will assess patients' decision self-efficacy, decisional conflict, shared decision-making experience, and decision regret using standardized questionnaires. It will also explore factors associated with better or worse decision quality, such as demographic characteristics, clinical information, health literacy, doctor-patient communication, family involvement, and emotional status.\n\nNo treatment or intervention will be assigned by the study. Participants will receive routine clinical care, and study data will be collected mainly through questionnaires before surgery or during the preoperative period. The findings may help clinicians identify patients who need additional decision support and improve communication during preoperative decision-making for suspected lung cancer.",[24,25,26],"Pulmonary Nodule","Suspected Lung Cancer","Preoperative Decision-Making",[28,29,30,31,32,24,25,33,26,34],"Shared Decision Making","Decisional Conflict","Decision Self-Efficacy","Decision Quality","Decision Regret","Thoracic Surgery","Patient-Centered Care","NOT_YET_RECRUITING","2026-05-14",{"date":38,"type":39},"2026-05-18","ACTUAL",{"date":41,"type":20},"2026-05",{"date":43,"type":20},"2027-07-31",{"name":45,"class":46},"Sichuan Cancer Hospital and Research Institute","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":21,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100453972","shared-decision-making-in-patients-with-lung-cancer-100453972","NCT05191485","Shared Decision Making in Patients With Lung Cancer","Shared Decision Making in Patients With Lung Cancer After Surgery：a Molecular Testing Decision Aid Evidence Based Development Study","Inclusion criteria:\n\nPatients of decision-making need assessment:\n\n1\\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have or have not made a decision on lung cancer molecular testing (whether to perform molecular testing or not).\n\nOther stakeholders of decision-making need assessment:\n\n1\\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.\n\nPatients of Cognitive debriefing\u002FAlpha tests:\n\n1\\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have made a decision on whether to perform lung cancer molecular testing or not.\n\nother stakeholders of Cognitive debriefing\u002FAlpha tests:\n\n1\\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.\n\nPatients of field testing \u002FBeta tests:\n\n1\\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have not decided whether to perform lung cancer molecular testing or not.\n\nClinician of field testing \u002FBeta tests:\n\n1\\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; and 4) voluntarily participated in this study.\n\nExclusion criteria:\n\nInability to understand the research content.",true,{"count":57,"type":20},190,"1 Day","The objective of this study is to develop a Decision Aid for Lung Cancer Molecular Testing (DA\\_LCMT) and to facilitate shared-decision making in patients who were diagnosed with lung adenocarcinoma by intraoperative frozen pathology about whether to conduct the molecular testing.",[61,62],"Surgery","Lung Adenocarcinoma",[64,65],"Shared-decision making","Decision aid","RECRUITING","2026-04-26",{"date":69,"type":39},"2026-04-30",{"date":71,"type":39},"2023-02-22",{"date":73,"type":20},"2027-12",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":96,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":47},"100636153","phase-2-tislelizumab-plus-chemotherapy-and-bace-for-unresectable-nsclc-100636153","NCT07561983","Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC","Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)","BEACON-Lung","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)\n* Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system\n* Initially unresectable disease as determined by multidisciplinary team (MDT) assessment\n* At least 1 measurable intrapulmonary lesion according to RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Forced expiratory volume in the first second (FEV1) \\> 1.0 L and \\> 40% of predicted normal value\n* Estimated life expectancy of at least 3 months\n* Adequate organ function\n* Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment\n* Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Ability to understand and willingness to sign a written informed consent form\n\nExclusion Criteria:\n\n* Prior local therapy for NSCLC, including radiotherapy or interventional therapy\n* Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations\n* Distant organ metastasis\n* History of another malignancy within the past 5 years\n* Active autoimmune disease or history of autoimmune disease requiring systemic treatment\n* Known allergy to any study drug or excipient\n* Interstitial lung disease, non-infectious pneumonitis, chronic obstructive pulmonary disease, or other uncontrolled systemic diseases judged to interfere with study treatment\n* Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including active tuberculosis\n* Major surgery requiring general anesthesia within 4 weeks before first dose\n* Any medical condition, alcohol or drug abuse, or dependence that may interfere with study treatment, interpretation of results, or increase treatment risk\n* Participation in another interventional therapeutic clinical study\n* Psychiatric illness or history of psychotropic drug abuse that may compromise study participation\n* Any condition judged by the investigator to make the patient unsuitable for the study","80 Years",{"count":85,"type":20},39,"INTERVENTIONAL",[88],"PHASE2","The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The main questions it aims to answer are:\n\n* What is the 1-year event-free survival (EFS) rate with this treatment?\n* Can this treatment improve tumor response and the chance of curative-intent resection?\n* What adverse events occur during treatment?\n\nParticipants will receive tislelizumab, intravenous chemotherapy, and BACE for up to 4 cycles. Tumor response and resectability will be evaluated by imaging and multidisciplinary team (MDT) assessment every 2 cycles. Participants who become resectable may undergo surgery followed by postoperative treatment per protocol. Participants who remain unresectable after 4 cycles will receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation. Regular follow-up will be performed for efficacy and safety assessment.",[91,92,93,94,95],"Unresectable Stage III Non-small Cell Lung Cancer","Tislelizumab","Chemotherapy","Chemoembolization, Therapeutic","Conversion Therapy",[97,92,93,98,95],"Unresectable Non-Small Cell Lung Cancer","Bronchial Artery Chemoembolization","2026-04-24",{"date":101,"type":39},"2026-05-01",{"date":101,"type":20},{"date":104,"type":20},"2028-12-31",{"name":45,"class":46},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":4},"100613693","application-of-multimodal-mri-in-histological-grading-and-prognostic-assessment-of-rectal-cancer-100613693","NCT07269912","Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer","Sub-region Analysis Based on Intravoxel Incoherent Motion MRI for Preoperative Prediction of Lymphovascular Invasion and Prognosis in Rectal Cancer","Inclusion Criteria:\n\n* (1) patients underwent preoperative abdominal pelvic IVIM-MRI examination; (2) patients underwent surgical resection within 2 weeks after IVIM-MRI examination; (3) complete postoperative pathological data, including LVI status.\n\nExclusion Criteria:\n\n* (1) radiotherapy or chemotherapy before surgery; (2) preoperative metastatic disease; (3) poor image quality; (4) incomplete clinical data.",{"count":114,"type":20},400,"Rectal cancer (RC) is among the most prevalent gastrointestinal cancers \\[1\\], characterized by significant tumor heterogeneity \\[2\\]. Neoadjuvant chemoradiotherapy followed by total mesorectal excision is a standard treatment for locally advanced rectal cancer \\[3\\]. Although the locoregional recurrence rate has decreased due to this treatment, distant metachronous metastases still occur in over 20-30% of cases \\[4,5\\]. The varying biological characteristics of rectal cancer may result in different treatment responses and prognoses \\[6\\]. Patients who are diagnosed with the same tumor-node-metastasis (TNM) stage of RC frequently exhibit vastly different clinical outcomes, despite receiving the same therapeutic interventions \\[7\\]. While the TNM staging system remains the predominantly used framework for directing treatment choices and forecasting prognosis, it is crucial to take into account additional pathological elements, such as tumor budding, lymphovascular invasion (LVI), perineural invasion, and extramural venous invasion \\[8-10\\]. A recent investigation has highlighted that LVI, rather than the traditionally prioritized extent of tumor invasion, serves as a significant risk factor for metastasis in early-stage RC \\[11\\]. Patients exhibiting LVI+ demonstrate a considerably worse prognosis and overall survival when compared to those with LVI -. Identifying LVI before surgery is crucial for informing treatment strategies in RC \\[12\\]. LVI offers important information regarding the tumor's biological behavior and its likelihood of metastasizing, thus improving the precision of disease staging. This information enables clinicians to tailor treatment approaches, which helps prevent overtreatment in patients with LVI -. In cases where LVI is present, it may be essential to adopt more aggressive treatment methods, such as postoperative chemotherapy, radiotherapy, or more extensive surgical resections, to reduce the chances of recurrence and metastasis. In summary, LVI serves as a crucial prognostic factor, providing essential insights into the tumor's potential for metastasis and recurrence, which has significant clinical implications for predicting postoperative outcomes, including recurrence, metastasis, and disease-free survival. Therefore, a preoperative non-invasive assessment of LVI, particularly in patients with LVI +, may be instrumental in guiding clinical practice.\n\nConventional magnetic resonance imaging (MRI) is particularly effective in observing large blood vessels and has moderate sensitivity and high specificity to distinguish LVI \\[13\\]. However, it can noninvasively and accurately assess extramural vascular invasion with a diameter greater than 3 mm. In contrast, it is challenging to evaluate vascular invasion with a diameter less than 3 mm, as well as intramural vascular and lymphatic infiltration, due to the limitations in resolution \\[14,15\\]. In addition, pathological biopsy is the gold standard for preoperative diagnosis. However, this invasive approach may not reflect the LVI status of the entire tumor due to possible sample errors \\[16\\]. Therefore, effectively assessing LVI in RC via preoperative imaging remains a significant challenge.\n\nIntravoxel incoherent motion (IVIM) is a functional imaging method that can display the diffuse movement of water molecules and blood flow, microcirculation perfusion, thereby improving the diagnostic accuracy of RC \\[17,18\\]. The IVIM model has the potential to identify perfusion effects using multiple b-value samples and biexponential curve fit analysis \\[19\\], which can lead to three parameters, namely the true diffusion coefficient (D), the pseudo-diffusion coefficient (D\\*), and the perfusion fraction (f). Li et al \\[20\\]. discovered that the D value obtained from IVIM of LVI+ patients was significantly higher than that of LVI- patients with RC, but only 42 patients were included in this study, making it more difficult to accurately assess the feasibility of IVIM. In another study, Kan et al \\[21\\]. revealed that the D value was helpful to assess the prognostic factor related to RC, while the AUC of the D value for evaluating LVI was only 0.646. Currently, studies utilizing conventional IVIM quantitative parameters have demonstrated a relatively low diagnostic efficiency in detecting LVI, with AUC values ranging from 0.629 to 0.646 \\[22,23\\].\n\nTumor heterogeneity has emerged as a significant biomarker for tumor staging and prognosis \\[24\\]. Sub-region analysis, an innovative imaging post-processing technique, has demonstrated its potential in exploring intratumor heterogeneity in recent years. Prior research has underscored the importance of sub-region analysis derived from either single-modality or multiparametric MRI in the investigation of intratumor heterogeneity in RC \\[25-27\\]. However, to our knowledge, the application of sub-region analysis based on IVIM-MRI to evaluate LVI status and prognosis in patients with RC has not been reported. Thus, this study aimed to assess the fe",[117,118],"Rectal Neoplasms","Prognosis","2025-11-26",{"date":121,"type":39},"2025-12-08",{"date":123,"type":20},"2027-11-01",{"date":123,"type":20},{"name":45,"class":46},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":132,"targetDuration":4,"studyType":86,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":47},"100606171","construction-and-empirical-research-of-the-applicable-baduanjin-protocol-for-patients-with-colorectal-cancer-enterostomy-100606171","NCT07172087","Construction and Empirical Research of the Applicable Baduanjin Protocol for Patients With Colorectal Cancer Enterostomy","Inclusion Criteria:\n\n1. The disease diagnosis is colorectal cancer\n2. At present, enterostomy is used for excretion, and the enterostomy time is more than one month\n3. Age ≥ 18 years old\n4. Have normal cognitive and expression abilities\n5. Voluntarily participate in this study and have signed the informed consent form.\n\nExclusion Criteria:\n\n1. In the past three months, I have participated in any intervention research or traditional Chinese medical exercise training programs (such as Tai Chi, Baduanjin, other Qigong exercises, etc.)\n2. Patients with severe functional disorders of the heart, lungs, liver, kidneys and other organs\n3. Mental abnormalities and language expression disorders\n4. Patients with limb dysfunction who are unable to cooperate in completing the Baduanjin training\n5. Various drainage tubes, PICC catheters, etc. were retained -",{"count":133,"type":20},258,[135],"NA","The goal of this clinical trial is to understand the application effect of the applicable version of Baduanjin protocol in patients with enterostomy and verify the safety and efficacy of this protocol. The main questions it aims to answer are:\n\nCan the applicable version of Baduanjin protocol be safely and effectively applied to patients with enterostomy? Researchers will compare the applicable version of the Baduanjin exercise with the walking exercise to see if the applicable version of the Baduanjin regimen is safe and effective for patients with enterostomy.\n\nParticipants will:\n\nApply the version of Baduanjin exercise or walking exercise five times a week for 12 weeks Patients signed in to the researchers of the project through forms such as exercise record sheets, videos uploaded on wechat, and records made through the keep app.",[138],"Colorectal Cancer",[140],"Baduanjin","2025-09-11",{"date":143,"type":39},"2025-09-15",{"date":145,"type":20},"2025-09",{"date":147,"type":20},"2026-12",{"name":45,"class":46},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":86,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":47},"100534877","study-on-the-safety-and-efficacy-of-mr-linac-technique-in-patients-with-unresectable-locally-advanced-colon-cancer-100534877","NCT06244537","Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer","UNLACC","Inclusion criteria:\n\n1. Patients over 18 years old\n2. Patients can remain in a stationary position on the treatment bed for 1-1.5 hours\n3. ECOG score 0-1\n4. Pathological diagnosis of colon adenocarcinoma, clinical stage cT4N0-2M0\n5. Organ function is normal, and the following conditions are required: white blood cell count ≥3.5×10\\^9\u002FL; platelet count ≥100×10\\^9\u002FL; hemoglobin ≥90g\u002FL. Total bilirubin level ≤1.5× upper limit of normal (ULN); AST and ALT levels ≤2.5 × ULN; endogenous creatinine clearance rate: 56-122ml\u002Fmin; serum creatinine \\\u003C1.0× ULN; serum albumin ≥30g\u002FL.\n6. Able to adhere to the study protocol during the research period\n7. Signed written informed consent\n\nExclusion Criteria:\n\n1. Patients with dMMR or MSI-H\n2. Presence of other types of tumors in addition to colon adenocarcinoma\n3. Claustrophobia or inability to undergo MRI or treatment due to the presence of metal implants or other reasons\n4. Distant metastasis (M1)\n5. Pregnant or lactating women\n6. Previous anti-tumor treatment\n7. Concurrent use of prohibited drugs for treatment\n8. Known history of positive human immunodeficiency virus testing or known acquired immunodeficiency syndrome.\n9. Clinically significant (i.e., active) cardiovascular disease: cerebrovascular accident\u002Fstroke (\\\u003C6 months prior to enrollment), myocardial infarction (\\\u003C6 months prior to enrollment), unstable angina pectoris, congestive heart failure (≥New York Heart Association class II) or severe arrhythmia requiring medication treatment\n10. Individuals with uncontrolled epilepsy, central nervous system disorders or a history of mental illness, whose clinical severity may hinder signing informed consent or affect patient compliance with oral medication according to the investigator's judgement\n11. Organ transplant surgery requiring immunosuppressive therapy\n12. Severe, uncontrolled recurrent infections or other severe, uncontrolled comorbidities",{"count":157,"type":20},20,[135],"In this phase I single-arm clinical study, 20 patients with T4 unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy\u002F5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX. The study will assess patients' surgical R0 resection rate, pCR or cCR rate, PFS, OS, and related adverse effects of treatment, aiming to explore the feasibility, safety, and efficacy of MR-Linac in the treatment of unresectable locally advanced colon cancer.",[161],"Safety and Efficacy",[163,164,165],"MR-Linac","unresectable locally advanced colorectal cancer","neoadjuvant radiotherapy","2025-09-02",{"date":168,"type":39},"2025-09-09",{"date":170,"type":39},"2024-04-01",{"date":172,"type":20},"2027-12-31",{"name":45,"class":46},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":181,"targetDuration":4,"studyType":86,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":4},"100599300","the-efficacy-of-antegrade-and-retrograde-enemas-management-in-low-anterior-resection-syndrome-and-improving-the-rate-of-ileostomy-reversal-100599300","NCT07082699","The Efficacy of Antegrade and Retrograde Enemas Management in Low Anterior Resection Syndrome and Improving the Rate of Ileostomy Reversal","The Efficacy of Antegrade and Retrograde Enemas in the Management of Low Anterior Resection Syndrome and Improving the Rate of Ileostomy Reversal: A Single-Centre, Prospective Randomised Controlled Trial","Inclusion Criteria:\n\n1. According to the NCCN guidelines for the pathological diagnosis of rectal cancer, the patient has primary rectal adenocarcinoma;\n2. Age ≥ 18 years;\n3. Previously underwent rectal resection with prophylactic ileostomy via laparoscopy, robotics, or open surgery;\n4. Expected to undergo ileostomy reversal surgery within 1-2 months;\n5. Possesses normal cognitive and communication abilities;\n6. Voluntarily participates in this study and has signed an informed consent form.\n\nExclusion Criteria:\n\n1. American Society of Anesthesiologists (ASA) classification III or higher;\n2. Concurrent inflammatory bowel disease, Crohn's disease, or other intestinal diseases;\n3. Mental disorders, long-term use of psychiatric drugs;\n4. Contraindications to enemas.",{"count":182,"type":20},72,[135],"Anterior rectal resection has become the primary surgical treatment for rectal cancer. However, studies have reported that up to 80%-90% of patients who undergo anterior rectal resection experience varying degrees of defecation dysfunction after surgery, such as frequent bowel movements, urgent bowel movements, and faecal incontinence, known as low anterior resection syndrome (LARS). This can lead to a decline in quality of life after surgery and even partial loss of social functioning.",[186],"LARS - Low Anterior Resection Syndrome","2025-07-22",{"date":189,"type":39},"2025-07-24",{"date":191,"type":20},"2025-07-20",{"date":193,"type":20},"2026-12-30",{"name":45,"class":46},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":86,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":47},"100597745","a-real-world-study-of-the-efficacy-and-safety-of-pd-1-inhibitors-combined-with-chemoradiotherapy-in-lung-metastatic-nasopharyngeal-carcinoma-100597745","NCT07062484","A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. age of at least 18 years;\n2. Karnofsky Performance Status (KPS) ≥60;\n3. histologically confirmed nasopharyngeal squamous carcinoma;\n4. metastatic disease after primary standard treatment (patients who had metastatic diseases over six months after treatment);\n5. at least 1 measurable metastatic lesions in lung or mediastinal or pleura (imaging for distant metastases with FDG-PET\u002FCT or chest\u002Fabdomen CT with contrast);\n6. adequate renal , liver and bone marrow function.\n\nExclusion Criteria:\n\n1. previous treatment with an immune checkpoint inhibitor;\n2. recurrent disease;\n3. previous systemic chemotherapy for metastatic disease;\n4. symptomatic central nervous system metastases;\n5. a history of non-infectious pneumonitis that required glucocorticoids, or active autoimmune disease;\n6. severe organ dysfunction or not suitable for chemoradiotherapy;\n7. individuals that had serious kidney, heart, blood, nervous system, or liver diseases or psychiatric disorders;\n8. individuals that had taken part in any other clinical trials testing other drugs within 3 months of the present study;\n9. other patients whom researchers deemed unsuitable to participate in the study.",{"count":202,"type":20},600,[135],"This study is a retrospective real-world study. In this study, we plan to collect the clinical data of lung metastatic nasopharyngeal carcinoma patients who received PD-1 inhibitors and chemotherapy combined with or without radiotherapy.",[206],"Lung Metastatic Nasopharyngeal Carcinoma","2025-07-10",{"date":209,"type":39},"2025-07-14",{"date":211,"type":20},"2025-07",{"date":213,"type":20},"2025-12",{"name":45,"class":46},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":222,"minAge":17,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":86,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":47},"100479711","a-rct-on-the-preventive-effect-of-hfnc-on-postoperative-pulmonary-complications-in-patients-with-gynecologic-neoplasms-100479711","NCT05526534","A RCT on the Preventive Effect of HFNC on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms","A Randomized Controlled Trial on the Preventive Effect of Heated Humidified High Flow Nasal Cannula Oxygen Therapy on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms","Inclusion Criteria:\n\n* Patients with gynecologic Neoplasms, including benign gynecologic tumors and malignant gynecologic tumors, who are 18 to 90 years old and are scheduled for surgical treatment in our center shall receive plain chest CT scan within 1 week before surgery, and the estimated surgical time shall be ≥2 hours, and at least one of the following conditions shall be met:\n\n  1. Assess respiratory risk in surgical patients in Catalonia (ARRSPC) ≥45 points;\n  2. BMI≥30;\n  3. Moderate to severe asthma;\n  4. Moderate to severe chronic obstructive pulmonary disease (COPD);\n  5. Smoking history ≥20 packs\u002Fyear\n\nExclusion Criteria:\n\n1. Patients with lung metastasis of malignant tumor or primary lung malignant tumor;\n2. previous lung surgery or radiotherapy;\n3. the surgery involved segmental bowel resection.","FEMALE","90 Years",{"count":19,"type":20},[135],"Patients at high risk of post-operative pulmonary complications (PPC) will be screened out from gynecological tumor patients undergoing surgical treatment, and randomly assigned into the HFNC group and control group, which uses conventional nasal cannula oxygen therapy. The primary outcome is the incidence of PPC, including postoperative hypoxemia, atelectasis, pneumonia, etc. Secondary outcomes are the improvement of postoperative oxygenation, antibiotic use, length of hospital stay, adverse events related to oxygen therapy, etc.",[228,229,230],"Gynecologic Surgery","High-flow Nasal Cannula","Post-operative Pulmonary Complications","2025-05-20",{"date":233,"type":39},"2025-05-23",{"date":235,"type":39},"2022-11-01",{"date":237,"type":20},"2025-12-31",{"name":45,"class":46},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":245,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":4},"100588312","application-of-the-sg8-scale-in-real-world-geriatric-oncology-patients-100588312","NCT06939764","Application of the sG8 Scale in Real-World Geriatric Oncology Patients","Inclusion Criteria:\n\n1. Patients aged 65 years or older.\n2. Patients with confirmed malignant tumors based on definitive pathological data.\n3. Patients who are assessed by clinicians to have indications for systemic anti-tumor therapy.\n4. Patients with a survival time greater than 12 weeks.\n\nExclusion Criteria:\n\n1. Patients who do not meet the above inclusion criteria or are considered unsuitable for this study by the investigator due to other circumstances.\n2. Patients who are unwilling to cooperate in completing the sG8 scale assessment.\n3. Patients who do not understand the content of this study or are unwilling to participate.","65 Years",{"count":247,"type":20},346,"This study is a multicenter, prospective, observational study. The study included patients aged 65 and older with solid tumors requiring systemic anti-tumor therapy. All patients underwent screening using the sG8 scale before the start of treatment, followed by routine treatment based on a plan developed through clinician decision-making. The study did not intervene in any way with the patients' diagnosis and treatment, and relevant clinical data during the treatment process were recorded accurately for follow-up patients. Study data were obtained from the electronic medical record databases and hospital information systems of multiple centers, including Sichuan Cancer Hospital. Patient clinicopathological features, pathological diagnoses, clinical stages, previous treatment histories, as well as anti-tumor treatment regimens after patient enrollment, drug dosages per cycle, treatment start times, incidence and grades of adverse events (AEs), and tumor response were extracted and collected from the medical records. All data were entered, managed, quality-controlled, exported, and analyzed through a real-world data management platform (RWDMP).",[250,251],"Solid Cancers","Geriatric Assessment","2025-04-15",{"date":254,"type":39},"2025-04-23",{"date":256,"type":20},"2025-05-16",{"date":69,"type":20},{"name":45,"class":46},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":86,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":47},"100478313","phase-2-nituzumab-taixinsheng--a-prospective-randomized-double-blind-placebo-controlled-multicenter-phase-ii-clinical-study-on-the-efficacy-and-safety-of-combined-induction-chemotherapy-for-locally-advanced-nasopharyngeal-carcinomatreatment-of-locally-advanced-nasopharyngeal-carcinoma-100478313","NCT05508347","Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma","Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China","Inclusion criteria:\n\n1. Voluntarily participate and sign the informed consent in writing.\n2. Age: 18-70 years old, gender is not limited.\n3. Nasopharynx squamous cell carcinoma diagnosed by histopathology.\n4. Nasopharyngeal carcinoma 2018 AJCC (Eighth Edition) staging: t2-4n2m0 (metastatic lymph nodes have one of the following risk factors: the shortest length of the largest lymph node is ≥ 3cm or the lymph node is liquefied and necrotic or the lymph node envelope is invaded) or t1-4n3m0.\n5. Immunohistochemistry: EGFR (+).\n6. The primary tumor can be measured.\n7. Kaplan score \\> 70.\n8. Survival expectation ≥ 6 months.\n9. Women in childbearing period should ensure to take effective contraception during the study period.\n10. Hemoglobin (Hgb) ≥ 90 g \u002F L, white blood cell (WBC) ≥ 4 × 109 \u002F L, platelet (PLT) ≥ 90 × 109 \u002FL.\n11. Liver function: ALT and \u002F or ast \\\u003C 1.5 times the upper limit of normal value (ULN), and TBIL \\\u003C 1.5 times the upper limit of normal value (ULN).\n\nRenal function: serum creatinine \\\u003C 1.5 times the upper limit of normal value (ULN); Creatinine clearance rate shall not be lower than 60ml \u002F min.\n\nExclusion criteria：\n\n1. There is evidence of distant metastasis.\n2. The primary tumor or lymph node has been treated surgically (except biopsy).\n3. Patients with primary focus or lymph nodes who have received radiotherapy.\n4. Those who have received epidermal growth factor targeted therapy.\n5. The primary lesion has received chemotherapy or immunotherapy.\n6. Have had other malignant tumors (except non melanoma skin cancer or cervical carcinoma in situ).\n7. Subjects who have received other drug tests in the past 1 month.\n8. \\> grade I peripheral neuropathy.\n9. Pregnant or lactating women and women of childbearing age who refuse contraception during the treatment observation period.\n10. Those with severe allergic history or special constitution.\n11. A history of severe lung or heart disease.\n12. Known to be infected with HIV virus or active viral hepatitis.\n13. Received live vaccine within 30 days of the planned start of study drug treatment.\n14. Those who refuse or cannot sign the informed consent form.\n15. Drug or alcohol addicts.\n16. Persons with personality or mental illness, without or with limited capacity for civil conduct.","70 Years",{"count":268,"type":20},170,[88],"Nasopharyngeal carcinoma (NPC) is a head and neck tumor. Studies have shown that more than 70% of patients are diagnosed with locally advanced nasopharyngeal carcinoma at the time of initial diagnosis. The 3-year survival rate of locally advanced nasopharyngeal carcinoma after chemotherapy is over 90%, but 30% of patients still have recurrence and distant metastasis. Therefore, while improving the level of radiation therapy technology, we should study multidisciplinary comprehensive treatment methods and put forward the biological concept of \"cure\". Induction chemotherapy can effectively create better radiotherapy conditions for locally advanced nasopharyngeal carcinoma, especially for patients with large lesions, improve the treatment response rate, and may reduce the local recurrence and distant metastasis rate. After the end of neoadjuvant chemotherapy, compared with patients who only reached SD, patients who reached CR had a significant survival benefit; Other patients had a reduced rate of distant metastasis, which aroused our interest, although there was no obvious survival benefit. The national multicenter phase II clinical study showed that nitumab combined with radiotherapy significantly improved the 3-year survival rate of patients with locally advanced nasopharyngeal carcinoma compared with radiotherapy alone. According to the previous related research results, nitumab combined with induction chemotherapy or concurrent chemoradiotherapy has a certain effect on nasopharyngeal carcinoma without obvious adverse reactions. However, prospective studies on the short-term efficacy and safety of local advanced nasopharyngeal carcinoma combined with induction chemotherapy and concurrent chemoradiotherapy are still lacking (Taisheng ®）。",[272],"Nasopharyngeal Carcinoma","2025-04-07",{"date":275,"type":39},"2025-04-09",{"date":277,"type":39},"2022-04-20",{"date":279,"type":20},"2027-10-30",{"name":45,"class":46},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":288,"targetDuration":4,"studyType":86,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":298,"locationsCount":47},"100571254","retrograde-and-antegrade-enema-for-prevention-of-lars-after-lar-a-randomized-controlled-trial-100571254","NCT06717854","Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial","Retrograde and Antegrade Enema for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Based on the NCCN guidelines for the pathological diagnosis of rectal cancer, patients are identified as having Primary Rectal Adenocarcinoma.\n* ≥18 years.\n* For the first time, anterior rectal dissection combined with prophylactic ileostomy was performed using laparoscopic, robotic, and open techniques.\n* The patient exhibits normal cognitive and expressive abilities.\n* Informed consent was obtained for voluntary participation in the study.\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) Class III or higher.\n* A combination of other intestinal conditions, including inflammatory bowel disease and Crohn's disease.\n* Mental disorders and prolonged use of psychotropic medications.\n* The presence of contraindications to enema administration.",{"count":182,"type":20},[135],"The goal of this clinical trial is to learn if enema works to prevent low anterior resection syndrome (LARS) in adults. The main questions it aims to answer are:\n\n1. To describe the level of stoma adaptation before and after the patients received enemas during the stoma period as well as the levels and trends of LARS, bowel function, sleep quality, and quality of life after stoma reduction surgery\n2. To compare the effects and advantages and disadvantages of antegrade and retrograde enema, and to investigate whether these two types of enema can provide safe and effective preventive measures for the prevention of LARS, the improvement of bowel function, and the enhancement of sleep and quality of life in rectal cancer patients after low anterior resection.\n\nResearchers will compare antegrade enema, retrograde enema, and the standard of care to see if these two types of enema work to prevent LARS.\n\nParticipants will:\n\n1. Receive either antegrade or retrograde enema or no enema based on the standard of care at 1 month after anterior rectal resection, until the ileostomy reversal.\n2. Keep a diary of their symptoms.",[292],"Low Anterior Resection Syndrome","2025-03-25",{"date":295,"type":39},"2025-03-30",{"date":293,"type":20},{"date":193,"type":20},{"name":45,"class":46},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":223,"enrollmentInfo":306,"targetDuration":4,"studyType":86,"phases":308,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":47},"100582236","phase-1-trial-of-gum-chewing-to-enhance-the-restoration-of-intestinal-motility-in-colorectal-cancer-surgery-100582236","NCT06860685","Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery","A Non-randomised External Controlled Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Surgery","Inclusion Criteria:\n\n* Patients with newly diagnosed colorectal cancer\n* Undergo open or laparoscopic colorectal surgery\n* Able to give informed consent\n* With normal verbal skills\n\nExclusion Criteria:\n\n* Preoperative lower extremity dysfunction\n* Dysphagia before surgery\n* Patients who are discharged ,transferred to another hospital or die within 72\n* hours after surgery",{"count":307,"type":20},292,[309,88],"PHASE1","Surgery is one of the most frequent treatments of colorectal cancer. However, delayed restoration of intestinal motility is a common phenomenon in patients who undergo colorectal surgery, and may reduce comfort, prevent the early hospital discharge of patients and increase healthcare costs. Gum chewing is a kind of safe and easily accessible sham feeding to stimulate intestinal motility. In addition, prediction models were used to estimate the risk of delayed restoration of intestinal motility after colorectal surgery. Thus, this study is an External Controlled trial that will determine whether stratified application of gum chewing by risk prediction model will enhance restoration of intestinal motility and reduce healthcare costs in paitents undergoing open or laparoscopic colorectal surgery.",[312],"Colorectal Cancer (CRC)","2025-03-05",{"date":315,"type":39},"2025-03-06",{"date":317,"type":20},"2025-03-01",{"date":319,"type":20},"2025-08-31",{"name":45,"class":46},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":328,"targetDuration":4,"studyType":86,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":47},"100557013","phase-2-neoadjuvantadjuvant-cadonilimab-plus-chemotherapy-in-patients-with-resectable-pd-l1-negative-nsclc-100557013","NCT06532591","Neoadjuvant\u002FAdjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC","Neoadjuvant or Adjuvant Cadonilimab (PD-1\u002FCTLA-4 Bispecific Antibody) Plus Chemotherapy in Patients With Resectable Stage IB (≥4 cm) to IIIB(N2) PD-L1 Negative Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 70 years\n* Patients with non-small cell lung cancer diagnosed by pathologic histology or cytology, and the primary focus or lymph node metastasis test is clearly negative for EGFR\u002FALK\u002FROS1;\n* Tumor tissue PD-L1 expression TPS \\\u003C1%\n* Patients with resectable stage IB (≥4 cm) to IIIB (N2) NSCLC (according to the staging criteria of the American Joint Committee on Cancer, 7th edition)\n* Eastern Cooperative Oncology Group performance-status score of 0 or 1\n* No previous anticancer therapy\n* Patients had to have measurable disease according to the Response Evaluation Criteria in Solid Tumors, version 1.1, and pretreatment tumor tissue available to assess the expression of programmed death ligand 1 (PD-L1)\n* Normal function of major organs\n\nExclusion Criteria:\n\n* Patients with large cell carcinoma and mixed cell lung cancer, mixed with small cell lung cancer components;\n* Presence of locally advanced unresectable or metastatic disease;\n* Patients in whom imaging shows that the tumor has invaded a vital vascular perimeter or in whom, in the judgment of the investigator, there is a high likelihood that the tumor will invade a vital vessel and cause a fatal hemorrhage during the follow-up study; or patients in whom there is a significant cavitating or necrotic tumor in the lung;\n* Has undergone any systemic anticancer therapy for NSCLC, including cytotoxic drug therapy, immunologic drug therapy, experimental therapy;\n* Has undergone localized radiotherapy for NSCLC;\n* Patients who have had a cancer other than NSCLC in the five years prior to the start of treatment in this study. Patients with cancers other than NSCLC within five years prior to the start of treatment in this study. Excluding cervical carcinoma in situ, cured basal cell carcinoma, and epithelial tumors of the bladder \\[including Ta and Tis\\];\n* Allergy to cardunculizumab or any component of the chemotherapeutic agent;\n* Patients with the presence of any severe and\u002For uncontrolled disease\n* Previous interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis requiring hormonal therapy, or any active interstitial lung disease with clinical evidence;\n* Patients who have had a cerebrovascular accident (including temporary ischemic attack) and pulmonary embolism within 6 months;\n* Current peripheral neuropathy of ≥ CTCAE grade 2, except as a result of trauma; patients requiring total right lung resection; subjects who have had major surgery or severe trauma and whose effects of surgery or trauma have resolved less than 14 days prior to enrollment\n* Patients who are participating in another clinical study or who are less than 4 weeks from the end of treatment in the previous clinical study;\n* History of known severe hypersensitivity reactions to other monoclonal antibodies;\n* Pregnant or lactating women;\n* Previous history of definite neurologic or psychiatric disorders, including epilepsy or dementia;\n* Patients who, in the judgment of the investigator, may have other factors that could lead to termination of the study, such as other serious medical conditions or serious laboratory abnormalities or other family or social factors that could affect the safety of the subject or the collection of trial data and samples.",{"count":157,"type":20},[88],"The purpose of this study is to observe and evaluate the efficacy and safety of cadonilimab combined with chemotherapy in patients with resectable IB (≥ 4cm) - IIIB (N2) stage PD-L1 negative non-small cell lung cancer",[332],"NSCLC","2024-12-18",{"date":335,"type":39},"2024-12-20",{"date":337,"type":39},"2024-08-01",{"date":339,"type":20},"2025-10-01",{"name":45,"class":46},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":348,"targetDuration":4,"studyType":86,"phases":350,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":360,"leadSponsor":361,"locationsCount":47},"100569722","neoadjuvant-chemoradiotherapy-compared-to-neoadjuvant-chemotherapy-for-luminal-type-locally-advanced-breast-cancer-a-clinical-study-100569722","NCT06697938","Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study","NCRT-LABC","Inclusion Criteria:\n\n1. Pathologically confirmed invasive breast cancer ;\n2. Breast MRI showing stages IIB to IIIC (2017 AJCC 8th edition staging);\n3. Clinical staging confirmed by chest MRI and\u002For axillary ultrasound, as well as CT scans of the neck, abdomen, and pelvis, and bone scintigraphy, including T and N staging and assessment of distant metastasis;\n4. Karnofsky performance score ≥80 or ECOG performance status of 0-1;\n5. No history of allergies to doxorubicin, cyclophosphamide, paclitaxel\u002Fdocetaxel;\n6. No prior exposure to radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.\n\nExclusion Criteria:\n\n1. History of malignancy at other sites, excluding curable non-melanoma skin cancer and carcinoma in situ of the cervix;\n2. Inability to complete MRI;\n3. Inflammatory breast cancer;\n4. Bilateral or multifocal primary tumors;\n5. Active infection currently present; clinically evident heart disease; myocardial infarction or cerebrovascular accident within 6 months prior to enrollment.",{"count":349,"type":20},148,[135],"This study focuses on preoperative treatment modalities for luminal-type locally advanced breast cancer. Based on modern precision radiotherapy technologies such as MRI-Linac, CyberKnife, and VMAT, it aims to compare the pCR rate, breast conserving surgery (BCS) rate, progression-free survival (PFS), and treatment-related side effects between preoperative neoadjuvant chemotherapy and preoperative neoadjuvant SBRT combined with chemotherapy in patients with this type of breast cancer. The goal is to provide new strategic options for the preoperative treatment of luminal-type locally advanced breast cancer.",[353],"Breast Cancer",[355,165],"locally advanced breast cancer","2024-11-18",{"date":358,"type":39},"2024-11-20",{"date":356,"type":20},{"date":43,"type":20},{"name":45,"class":46},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":86,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":4},"100526691","intravenous-lidocaine-infusion-reduce-postoperative-pulmonary-complications-in-patients-undergoing-minimally-invasive-esophagectomy-100526691","NCT06138041","Intravenous Lidocaine Infusion Reduce Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy","Effect of Intravenous Lidocaine Infusion on Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy: a Double-center, Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\nPatients between 18 and 85 years of age with a recent schedule for MIE are screened for this study. Patients who show clear consciousness and ASA status I - III will be included as eligible participants.\n\nExclusion Criteria:\n\nThe exclusion criteria are as follows: patients with severe psychiatric disorders, such as schizophrenia, depression, dementia, etc.; severe hepatic insufficiency (concentration of glutamic oxaloacetic transaminase, glutamic pyruvic transaminase or bilirubin ≥2.5 times the upper limit of normal); renal impairment (creatinine clearance \\\u003C60 mL\u002Fmin); allergy to amide local anesthetics; history of seizures; presence of II\u002FIII atrioventricular block; patients with severe sinus bradycardia or sick sinus syndrome; patients with Adams-Stokes syndrome or pre-excitation syndrome; intracardiac block (e.g. complete bundle branch block, atrioventricular block); serum potassium ion concentration below 2.5 or above 5.0 mmol\u002FL; PH\\>7.55 or PH\\\u003C7.2. Patients will be discontinued if any of the following situations occur: the patient has an allergic reaction, severe cardiovascular events that cannot be managed with symptomatic treatment, and the patient is unwilling to continue the study.","85 Years",{"count":371,"type":20},770,[135],"The goal of this double-center, double-blind, randomized controlled clinical trial is to compare the effect of intravenous lidocaine infusion on postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy. The main question it aims to answer are whether intravenous lidocaine reduce postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy. Participants will be given intravenous lidocaine infusion in lidocaine group or placebo in control group.",[375,376,377],"Postoperative Pneumonia","Postoperative Pulmonary Atelectasis","Postoperative Pulmonary Edema","2024-10-20",{"date":380,"type":39},"2024-10-22",{"date":382,"type":20},"2025-02-01",{"date":384,"type":20},"2025-08-30",{"name":45,"class":46},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":55,"sex":222,"minAge":4,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":395,"conditions":396,"keywords":399,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":47},"100517545","a-cohort-establishment-study-of-total-management-of-ovarian-cancer-100517545","NCT06018935","A Cohort Establishment Study of Total Management of Ovarian Cancer","A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)","Inclusion Criteria:\n\n1. Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;\n2. Can cooperate with later follow-up.\n\nExclusion Criteria:\n\n1. Patients with other malignant tumors or previous history of other malignant tumors;\n2. Have cognitive impairment.",{"count":394,"type":20},500,"A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).",[397,398],"Tumor of Female Reproductive System","Ovarian Cancer",[400,401,402],"Ovarian cancer","Cohort study","Whole-process management","2024-06-17",{"date":405,"type":39},"2024-06-20",{"date":403,"type":39},{"date":408,"type":20},"2025-09-01",{"name":45,"class":46},{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":47},"100543878","real-world-study-of-lolatinib-for-advanced-alk-nsclc-patients-100543878","NCT06361589","Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients","Real World Study of Lolatinib for Patients With Advanced\u002FMetastatic Anaplastic Lymphoma Kinase (ALK) - Positive Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n1. Voluntary participation in this clinical study, understanding of study procedures, and ability to sign written informed consent.\n2. Age ≥18 years.\n3. Locally advanced or metastatic (inoperable stage IIIa or IIIb-IV) NSCLC with disease staging according to the American Joint Committee on Cancer (AJCC)\u002FUICC 8th edition lung cancer staging criteria.ALK fusion mutations confirmed by tumor histology or hematology.\n4. Expected survival greater than 12 weeks.\n5. Adequate bone marrow reserve, organ function, and coagulation as assessed by the investigator as evidenced by complete blood count, biochemical parameters in blood and urine, coagulation, and electrocardiogram or cardiac ultrasound at baseline.\n6. Can take the medicine orally and swallow it.\n7. Female patients of childbearing potential are willing to use appropriate contraception and should not breastfeed within 6 months from signing the main informed consent to efficacy evaluation\u002Fend of medication (whichever is later); Male patients were willing to use barrier contraception (i.e., condom) for 6 months from signing the main informed consent until the efficacy assessment\u002Fend of medication, whichever occurred later.\n8. Female patients have a negative blood pregnancy test within 3 days before enrollment or meet one of the following criteria to demonstrate no risk of pregnancy: a. Postmenopausal is defined as age 50 years or older and amenorrhea for at least 12 months after cessation of all exogenous hormone replacement therapy; b. Females less than 50 years of age may also be considered postmenopausal if they have been amenorrhoeic for 12 months or more after cessation of all exogenous hormonal therapy and have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels within the laboratory postmenopausal reference values; c. History of irreversible sterilization, including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, except for bilateral tubal ligation.\n\nExclusion Criteria:\n\n1. Use of strong CYP3A4 inhibitors, strong inducers, or drugs with a narrow therapeutic window that are sensitive substrates of CYP3A4 within 7 days and need to continue treatment with these drugs during the study.\n2. Patients with known active infectious diseases, such as active hepatitis B or C or HIV infection of human immunodeficiency virus, active hepatitis B and C including hepatitis B or C surface antigen (+) patients receiving intravenous treatment for infection - patients receiving oral antiviral suppression of hepatitis B or C will be allowed to participate in the study.\n3. Any other disease, metabolic abnormality, physical examination abnormality, or laboratory abnormality that, in the judgment of the investigator, has reason to suspect that the patient has a disease or condition that is not appropriate for the use of lorlatinib, or would affect the interpretation of the study results, or place the patient at high risk.\n4. Female patients who are pregnant, breastfeeding, or plan to become pregnant during the study.\n5. Patients with hypersensitivity to any active or inactive ingredient of lorlatinib.\n6. Any other patient who, in the judgment of the investigator, may have poor compliance with the study procedures and requirements.",{"count":19,"type":20},"This study was a multicenter, prospective, non-interventional clinical study that included first-line and late-line patients with advanced non-small cell lung cancer with ALK fusions treated with the third generation ALK-TKI lorlatinib until disease progression, intolerable toxicity, investigator or subject decision to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death. Clinical pathology including sex, age, ALK mutation status at diagnosis, and clinical stage at diagnosis were collected from medical records. Physical condition as assessed by ECOG-PS before administration of lorlatinib was also recorded. Treatment information was obtained from the records, including dose and timing of ALK-TKI therapy and tumor response, number of prior systemic lines of therapy, and local treatment modalities such as radiotherapy and surgery. Quality of life based on the EORTC QLQ C30+LC29 scale (plus the EORTC QLQ BN20 scale in patients with brain\u002Fmeningeal metastases) was performed at baseline and at each follow-up point. This study will use REDCap platform to collect and manage the study data information of multi-center patients.",[420,421],"ALK-positive Non-small Cell Lung Cancer","Real World Study","2024-04-09",{"date":424,"type":39},"2024-04-12",{"date":426,"type":20},"2024-05-01",{"date":428,"type":20},"2028-11-01",{"name":45,"class":46},{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":437,"enrollmentInfo":438,"targetDuration":4,"studyType":86,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":4},"100501314","reduced-dissemination-of-tumor-cells-with-primary-ligation-of-the-inferior-mesenteric-vein-in-rectal-cancer-patients-100501314","NCT05807646","Reduced Dissemination of Tumor Cells With Primary Ligation of the Inferior Mesenteric Vein in Rectal Cancer Patients.","Effect of Ligation Sequence of the Inferior Mesenteric Artery and Vein on Circulating Tumor Cells and Survival in Laparoscopic Rectal Cancer Surgery: a Prospective, Multicenter, Randomized Controlled Study (ARVECTS)","Inclusion Criteria:\n\n1. Age: 18-75 years;\n2. Histopathologically confirmed as rectal adenocarcinoma(tumor located within 15 cm from the anal verge at colonoscopy);\n3. Patients with a stage I-III rectal cancer eligible for surgery and R0 resection is expected, patients with pelvic lateral lymph nodes metastasis are ineligible;\n4. ECOG score: 0-1;\n5. ASA score: I\u002FII\u002FIII;\n6. Laparoscopic surgery;\n7. Informed consent.\n\nExclusion Criteria:\n\n1. Patients who have received preoperative treatment (such as preoperative radiotherapy and chemotherapy);\n2. Receiving transanal total mesorectal excision (taTME), specimen extraction through natural lumen (NOSES) ;\n3. Recurrent rectal cancer;\n4. Simultaneous or metachronous colorectal cancer;\n5. Malignant tumors of other organs in the past 5 years or at the same time;\n6. The results of preoperative physical examination and imaging examination showed that: (1) the tumor involved the surrounding organs and required combined organ resection; (2) distant metastasis; (3) could not be resected at R0;\n7. Pregnant or lactating women;\n8. Patients with severe mental disorder;\n9. It is not suitable for patients undergoing laparoscopic surgery (such as extensive adhesion caused by previous abdominal surgery or inability to tolerate artificial pneumoperitoneum);\n10. History of unstable angina pectoris or myocardial infarction in the past 6 months;\n11. Have a history of cerebrovascular accident in the past 6 months;\n12. Systemic administration of corticosteroids within 1 month before enrollment;\n13. Taking folic acid related drugs within half a year before operation.\n14. Severe cardiac insufficiency (FEV1\\\u003C50% of predicted values);\n15. Emergency surgery.","75 Years",{"count":439,"type":20},268,[135],"Effect of ligation sequence of the inferior mesenteric artery and vein on circulating tumor cells and survival in laparoscopic rectal cancer surgery: a prospective, multicenter, randomized controlled study (ARVECTS)",[443],"Rectal Cancer","2024-02-14",{"date":446,"type":39},"2024-02-15",{"date":448,"type":20},"2025-01",{"date":450,"type":20},"2028-12",{"name":45,"class":46},{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":222,"minAge":17,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":86,"phases":461,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":47},"100452574","phase-3-induction-chemotherapy-combined-with-immunotherapy-followed-by-concurrent-chemoradiation-in-advanced-cervical-cancer-100452574","NCT05173272","Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer","A Prospective Randomized Controlled Trials of Neoadjuvant Chemotherapy Combined With Serplulimab Followed by Concurrent Chemoradiation Versus Concurrent Chemoradiation Therapy Alone in Advanced Cervical Cancer","Inclusion Criteria:\n\n* Age ≥18 years old\n* Patients must have histologically confirmed cervical cancer with adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 Ib3-IIIc2.\n* According to the RECIST 1.1 standard, the subject must have at least one measurable target lesion\n* No prior treatment\n* Expected survival period ≥ 3 months\n* ECOG score: 0-1\n* No obvious signs of hematological diseases, ANC≥1.5×10\\^9\u002FL, platelet count≥100×10\\^9\u002FL, Hb≥90g\u002FL, WBC≥3.0×10\\^9\u002FL, and no bleeding tendency before enrollment;\n* Adequate hepato-renal function is needed, including: Total bilirubin (TBIL)≤1.5×ULN (Gilbert syndrome allows ≤5×ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN Serum creatinine (Cr) ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 50mL\u002Fmin\n* Cardiac Function: left ventricular ejection fraction (LVEF) \\>=50%;\n* Patients voluntarily participated in the study and signed informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding female patients (women of child-bearing potential must confirm that the pregnancy test is negative within 7 days before the first administration. If it is positive, ultrasound examination must be performed to exclude pregnancy), or women of child-bearing potential who refused to receive contraceptive measures\n* Combined with other malignant tumors, except for cured skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of any other part\n* Existence of any bone marrow dysplasia and other abnormal hematopoietic diseases\n* Active infections, HIV infections, and viral hepatitis that require systematic treatment\n* Patients with≥Grade 1 peripheral neuropathy according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 5.0\n* Had severe cardiovascular diseases such as cerebrovascular accident, myocardial infarction, hypertension that cannot be controlled after drug intervention, unstable angina pectoris, heart failure (NYHA 2-4) and arrhythmia that need drug intervention within 6 months\n* It is known to have a history of allergies to research drugs or drug components\n* Has clinically significant thyroid dysfunction before enrollment;\n* Has participated in other anti-tumor intervention clinical trials within 30 days before the first medication\n* Have a clear history of dementia, mental state changes or any mental illness that will hinder understanding or informed consent\n* The investigator believes that the patient is not suitable for participating in this clinical research",{"count":460,"type":20},286,[462],"PHASE3","The main objective of this study is to determine whether neoadjuvant chemotherapy combined with slulimumab sequential concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced cervical cancer could improve progression-free survival rates.\n\nWomen in the experimental arm will receive neoadjuvant chemotherapy (cisplatin plus paclitaxel) combined with slulimumab every 21 days during 2 cycles followed by concurrent chemoradiation therapy. Women in the control arm will receive concurrent chemoradiation therapy alone.\n\n286 patients will be recruited during 2 years, with 3 years of follow up period.",[465],"Cervical Cancer","2023-12-25",{"date":468,"type":39},"2023-12-27",{"date":470,"type":39},"2023-07-24",{"date":472,"type":20},"2028-12-28",{"name":45,"class":46},{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":437,"enrollmentInfo":481,"targetDuration":4,"studyType":86,"phases":483,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":491,"leadSponsor":493,"locationsCount":47},"100458067","phase-3-sintilimab-plus-nct-or-ncrt-versus-ncrt-for-escc-100458067","NCT05244798","Sintilimab Plus NCT or NCRT Versus NCRT for ESCC","Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy Plus Sintilimab Versus Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized, Controlled, Phase III Trial","Inclusion criteria:\n\n1. Aged 18 to 75, both sexes;\n2. Patients with histologically confirmed locally advanced (cT1N2-3M0 or cT2-4aN0-3M0) thoracic esophageal squamous cell carcinoma (8th UICC-TNM stage);\n3. Cervical contrast-enhanced CT showed no suspicious metastatic lymph nodes. Imaging examination showed no systemic metastasis.\n4. R0 resection is expected to be achieved;\n5. Physical state ECOG 0 \\~ 1;\n6. No previous antitumor therapy for esophageal cancer, including chemotherapy, radiotherapy (including radiotherapy planned during the study), hormone therapy, and immunotherapy;\n7. Measurable lesions (according to RECIST v1.1);\n8. There was no operation contraindications in the evaluation of various organ functions before operation;\n9. The following laboratory tests confirm that the bone marrow, liver and kidney functions meet the requirements for study participation:\n\n   * Hemoglobin ≥90g\u002FL;\n   * White blood cell count ≥ lower limit of laboratory normal;\n   * Neutrophil absolute value (ANC) ≥1.5×109\u002FL;\n   * Platelet count ≥100×109\u002FL; Total bilirubin ≤1.5× upper limit of normal (ULN);\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN;\n   * Prothrombin time ≤16 seconds and international normalized ratio ≤1.5×ULN; Creatinine ≤1.5×ULN or Cr clearance ≥50 mL\u002Fmin (calculated using Cockcroft-Gault formula);\n10. Fertile women must consent to use effective contraception (e.g. intrauterine devices, birth control pills, or condoms) during the study medication period and within 60 days of the last study medication, have a negative serum pregnancy test within 7 days before study enrollment, and be non-lactating; Men agree that they must use effective contraception during the study medication period and for 60 days after the last study medication;\n11. The informed consent must be understood and signed.\n\nExclusion criteria:\n\nPatients who met any of the following criteria were excluded from the study:\n\n1. Malignant tumors other than esophageal cancer (cured localized tumors, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ, were not excluded) had occurred within 5 years before randomization; Prostate cancer patients receiving hormone therapy with DFS for more than 5 years were not excluded).\n2. Patients with high blood tendency who had a history of gastrointestinal bleeding within 6 months before randomization, or had coagulopathy at the time of enrollment, or were receiving thrombolysis or anticoagulant therapy;\n3. Severe cardiovascular and cerebrovascular diseases:\n\n   • New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, myocardial infarction, poorly controlled arrhythmias, or cerebrovascular accidents within 12 months before randomization.\n\n   LVEF (left ventricular ejection fraction) \\\u003C50% on echocardiography. Corrected QT interval (QTc) \\>480ms (calculated using Fridericia's method; if QTc was abnormal, three consecutive tests were performed at 2 min intervals and the mean value was taken).\n\n   Medically difficult to control hypertension (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100mmHg) (based on the average of ≥2 measurements).\n\n   • A previous hypertensive crisis or hypertensive encephalopathy.\n4. Previous history of interstitial lung disease or pneumonia requiring steroid treatment at enrollment;\n5. Had active tuberculosis at the time of randomization, or had received anti-tuberculosis therapy within 1 year before randomization;\n6. Asthma at random requiring intermittent use of bronchodilators or other medical interventions;\n7. Patients with infectious diseases requiring systemic treatment (oral or intravenous administration) within 4 weeks before randomization; for active hepatitis, effective treatment was required before enrollment;\n8. Severe unhealed wounds, active ulcers, and untreated fractures at random;\n9. Combined with other inoperable conditions;\n10. The previous operation resulted in the inability to use stomach instead of esophagus to reconstruct the digestive tract in this operation;\n11. Was receiving systemic steroid therapy (more than 10mg of prednisone daily or equivalent) or other immunosuppressive agents during the 2 weeks prior to randomization;\n12. Severe allergy to chemotherapy drugs (albumin paclitaxel or cisplatin) or any monoclonal antibody;\n13. Has had an active autoimmune disease requiring systemic treatment (i.e., immunomodulatory drugs, corticosteroids, or immunomodulatory drugs) in the past 2 years; However, replacement therapy (e.g., thyroxine, insulin, or replacement therapy with physiologic corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy and is allowed for use and enrollment;\n14. Previous organ transplant recipients;\n15. If HBsAg(+) and\u002For HBcAb(+) are required, HBV DNA must be \\\u003C 500IU\u002FmL. (If the lower limit of the local center's minimum detectable value is higher than 500IU\u002FmL, after discussion with the sponsor, Enrollment was determined on a case-to-case basis) and continued to receive effective anti-HBV therapy that was already in use during the study period, or entecavir or tenofovir therapy was started prior to study medication;\n16. Hcv-rna testing should be performed if HCV antibody is positive, and HCV-RNA\\>10\\^3 copy number \u002FmL should be excluded;\n17. Co-infection with HIV;\n18. In the judgment of the investigator, there are other circumstances that are not suitable for participating in the study.",{"count":482,"type":20},420,[462],"Comparative analysis of patients with resectable locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy combined sintilimab versus neoadjuvant chemoradiotherapy.",[486],"Esophageal Squamous Cell Carcinoma","2022-10-24",{"date":489,"type":39},"2022-10-25",{"date":235,"type":20},{"date":492,"type":20},"2026-12-31",{"name":45,"class":46},""]